The class 1A aldehyde dehydrogenase (ALDH1A) subfamily of genes encode enzymes that function at the apex of the retinoic acid (RA) signalling pathway. We detected aberrant expression of ALDH1A genes, particularly ALDH1A2, in a majority (72%) of primary paediatric T cell acute lymphoblastic leukaemia (T-ALL) specimens. ALDH1A expression was almost exclusive to Tlineage, but not B-lineage, ALL. To determine whether ALDH1A expression may have relevance to T-ALL cell growth and survival, the effect of inhibiting ALDH1A function was measured on a panel of human ALL cell lines. This revealed that T-ALL proliferation had a higher sensitivity to modulation of ALDH1A activity and RA signalling as compared to ALL cell lines of B-lineage.
. Recent evidence suggests that aberrantly expressed oncogenes in T-ALL cause leukaemic transformation by promoting thymocyte proliferation, survival and/or differentiation arrest (McCormack et al, 2010; Dadi et al, 2012) . However, a full account of the mechanisms that mediate T cell transformation remains to be achieved.
The class 1A aldehyde dehydrogenase (ALDH1A) subfamily of genes, responsible for cellular retinoic acid (RA) synthesis (Molotkov & Duester, 2003) have provided a possible link between the distinct molecular T-ALL subtypes, having been identified as being downstream of both TLX and TAL1/LMO proteins. Family member ALDH1A1, which is not expressed in normal thymocytes, is transcriptionally regulated by TLX1 in multiple cell types including T cells (Greene et al, 1998; Rice et al, 2008) , while the highly related ALDH1A2 is a target gene of TAL1/LMO proteins in T-ALL (Ono et al, 1998; Palomero et al, 2006; Sanda et al, 2012) . ALDH1A enzymes (also known as retinal dehydrogenases [RALDHs] ) are of interest because the product of their activity, the hormone/morphogen RA, is an essential regulator of diverse biological processes via activation of nuclear receptors. Crucially, this includes haemopoiesis where synthesis of RA by ALDH1A enzymes has been implicated in the regulation of haemopoietic stem cell (HSC) development, differentiation and renewal (Chute et al,2006; Muramoto et al, 2010; Ma et al, 2010; Chanda et al, 2013; Ghiaur et al, 2013) . Thus, high ALDH1A activity is a prominent feature of HSCs (Armstrong et al, 2004) , being associated with enhanced repopulating ability and resistance to cytotoxic drugs, such as cyclophosphamide (Colvin et al, 1988) , and exploited practically for their purification (Hess et al, 2004) . Moreover, in haemopoietic progenitors ALDH1A expression appears to have a role in regulating the polarity of differentiation towards a myeloid rather than a lymphoid cell fate (Storms et al, 2005; Rice et al, 2008) , an effect mirrored by the administration of RA alone (Purton et al, 1999; Leung & Verfaillie, 2005) . Significantly, RA is known to promote the proliferation (Dillehay et al, 1989; Ertesvag et al, 2002; Engedal et al, 2006) and survival (Engedal et al, 2004) of human T cells, while inhibiting thymocyte differentiation (Zhou et al, 2008) . This is in contrast to many other cell types, including B cells (Naderi & Blomhoff, 1999) , where RA primarily appears to act as an anti-proliferative and pro-differentiation agent.
To gain insight into the importance of aberrant ALDH1A subfamily gene expression in T-ALL, we examined gene expression microarray data in primary tumours from 100 children with this disease compared to 55 children with B-lineage ALL. We found that ALDH1A genes, particularly ALDH1A2, were expressed at a high frequency specifically in T-ALL. The effect of blocking ALDH1A activity was then examined, which revealed that these enzymes selectively contribute to the growth and survival of ALL cells of T cell phenotype. These results implicate ectopic RA synthesis and subsequent modulation of gene expression via the retinoid signalling pathway as a contributing factor in T-ALL tumorigenesis.
Materials and Methods

Cell lines
The ALL cell lines PER-117, PER-255, PER-604, PER-377 and PER-495 have been described previously (Kees et al, 2003) and characterized cytogenetically and molecularly Hoffmann et al, 2006; Beesley et al, 2010) . The CEM cell line was obtained from the Children's Cancer Institute Australia for Medical Research. Cell lines were cultured in a humidified atmosphere with 5% CO 2 in RPMI 1640 medium supplemented with 2 mmol/l L-glutamine, 10 nmol/l 2-mercaptoethanol and 10% heat-inactivated fetal calf serum (FCS; CSL, Melbourne, VIC, Australia).
All PER cell lines were additionally supplemented with 1 mmol/l sodium pyruvate and non-essential amino acids. For PER-255, PER-604 and PER-377, 20% FCS was used. Cell lines were cultured in the absence of antibiotics and testing for mycoplasma was routinely performed by polymerase chain reaction (PCR).
ALDH assay
To determine cell line ALDH enzyme activity, 5 × 10 5 cells were incubated with Aldefluor reagent (StemCell Technologies, Vancouver, BC, Canada) at 37°C for 30 min in the presence or absence of the ALDH inhibitor diethylaminobenzaldehyde (DEAB, 10 μmol/l). Sytox staining (Life Technologies, Carlsbad, CA, USA) was used to determine viability. After staining, cells were pelleted and resuspended in 500 μl Aldefluor assay buffer. The cell suspensions were analysed on an LSRII flow cytometer (BD Biosciences, San Jose, CA, USA). ALDH activity was determined by the net change in mean fluorescence intensity between DEAB-inhibited and uninhibited viable cells. All flow cytometric data were subsequently analysed using FlowJo software (TreeStar, Ashland, OR, USA).
Proliferation assay
Cells in exponential growth phase were counted by trypan blue exclusion and seeded in fresh media at a density of 0·5-1·5 × 10 6 cells/ml in the presence or absence of various concentrations of 3,7-dimethyl-2,6-octadienal (citral; Sigma Aldrich, St. Louis, MO, USA), or 75 μmol/l citral plus various concentrations of (E)-4- [2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl 
prop-1-enyl] benzoic acid (Ro 41-5253; Enzo Life Sciences, Farmingdale, NY, USA) dissolved in dimethyl sulphoxide (DMSO), or DMSO alone, for 48 h. The final concentration of DMSO in the medium was 0·1%, which had no effect on cell viability. Testing was performed in triplicate using the following ranges: citral: 10-200 μmol/l, TTNPB: 0·6-12 μmol/l; Ro 41-5253: 2·5-50 μmol/l. Culture plates (96-well) were incubated at 37°C for 42 h prior to the addition of 10 μl of filter-sterilized 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/ml). Plates were then incubated for a further 6 h before addition of 100 μl acidified isopropyl alcohol solution to dissolve formazan crystals and measurement of absorbance at 595 nm on a microplate reader (Wallac Victor 2
Multi-label Counter 1420; Perkin Elmer, Waltham, MA, USA). Data represent the average of at least three independent experiments and were reported as an IC25/SC25 (concentration that inhibited or stimulated cell growth by 25%).
Microarray data analysis
Gene expression profiling of the primary patient cohort analysed in this study has been previously described (Cleaver et al, 2010) and comprised bone marrow specimens obtained at diagnosis from 50
T-ALL patients at either Princess Margaret Hospital, Perth, Australia or provided by the Children's Oncology Group (COG). Expression data from an additional 50 T-ALL patients was obtained from two cohorts reported by Winter et al (2007) and normalized by robust multi-array analysis (RMA) as previously described (Cleaver et al, 2010) . We corrected for batch effects across the data sets using
ComBat (Johnson et al, 2007) . Affymetrix Human Genome U133 Plus 2·0 expression microarray data from two normal human thymus glands were obtained from the NCBI GEO database (Edgar et al, 2002) , accession numbers GSM175973 and GSM176262. Affymetrix Human Genome U133A expression data were also obtained for six ALL cell lines (Hoffmann et al, 2006; Beesley et al, 2010) . We used hierarchical clustering with Euclidean distance and complete linkage in generating the heat maps. The probes used to represent each gene were 212224_at (ALDH1A1),
203750_s_at (RARA). The probes were selected for their presence in both microarray formats used, their reliability, signal strength and resolution.
Quantitative real-time PCR
Cells were cultured in duplicate for 16 h in the presence of 100 μmol/l citral, or control media containing vehicle only. Total RNA was extracted from cells by TRIzol lysis (Life Technologies), phenol extraction and ethanol precipitation. First strand cDNA was generated from 1 μg of total RNA using oligo-dT primer (Life Technologies) and Omniscript reverse transcriptase (QIAGEN, Hilden, Germany). ALDH1A1, ALDH1A2 and TNFRSF10B (tumor necrosis factor receptor superfamily, member 10b, also termed TRAIL-2) expression was measured using TaqMan gene expression assays Hs00946916_m1, Hs00180254_m1 and Hs00366278_m1, respectively (Life Technologies) on onehundredth of the cDNA. Reactions (20 μl) were performed in triplicate in 384-well plates on an ABI 7900HT Fast Real-Time PCR System (ABI, Grand Island, NY, USA). Gene expression was normalized using the TaqMan RPL19 expression assay Hs02338565_gH.
Statistical analyses
Gene expression correlations with ALDH1A were determined using Pearson's correlation coefficient calculated using expression data of 102 samples (patient samples plus two normal thymus samples).
Associated P-values were corrected using the method of Benjamini and Hochberg (1995) ; P-values ≤0·05 were considered to be statistically significant. Nested analysis of variance (anova) was used to test for differences in IC25 values between T-and B-lineage ALL cell lines. The two-sample t test was used to assess differences in mRNA transcript levels determined by quantitative reverse transcription polymerase chain reaction (RT-PCR).
Results
ALDH1A genes are aberrantly expressed at high frequency in T-ALL
Genes encoding ALDH1A enzymes, whose main physiological function is cellular RA synthesis, are known to lie downstream of two oncogenic transcription factors aberrantly expressed in T-ALL, namely TLX1 in the case of ALDH1A1 (Greene et al, 1998; Rice et al, 2008) and TAL1 (SCL) in the case of ALDH1A2 (Ono et al, 1998; Palomero et al, 2006; Sanda et al, 2012) . This prompted the hypothesis that transcription of ALDH1A genes may be a common feature of T-ALL. We therefore examined ALDH1A subfamily (ALDH1A1, ALDH1A2 and ALDH1A3) gene expression in 100 primary T-ALL tumour specimens using microarray data from two published datasets (Winter et al, 2007; Cleaver et al, 2010) . Elevated levels of ALDH1A1, ALDH1A2 and ALDH1A3 mRNA expression were detected in 13%, 63% and 3% of T-ALL samples, respectively, and a total of 72% of the primary samples expressed at least one of these three genes ( Fig 1A; Table 1 ). Thus, ALDH1A genes are expressed at a high frequency in T-ALL, with ALDH1A2 expression being particularly prominent, both in terms of frequency and absolute levels of expression. ALDH1A2 was highly overexpressed with a mean fold-change of 7·52 (P = 0·007) when microarray data were used to compare expression between the panel of 100 T-ALL tumours and two normal human thymus specimens. In contrast, examination of ALDH1A2 expression using published microarray data from a cohort of 55 primary pre-B lineage ALL specimens (Hoffmann et al, 2008) , revealed that it was not significantly expressed in any cases (Fig 1B) . Overall, ALDH1A1, ALDH1A2 and ALDH1A3 mRNA transcripts were detected in 4%, 0% and 0% of 55 pre-B ALL samples, respectively. Thus, aberrant expression of genes encoding ALDH1A enzymes is almost exclusively associated with ALL tumours of T cell lineage.
Consistent with previous observations (Ono et al, 1998) , TAL1, which was expressed in 54% of tumours, showed significant correlation with that of ALDH1A2 (r = 0·42). Nevertheless, these data also indicate that additional mechanisms besides TLX1 and TAL1 are responsible for aberrant ALDH1A1 and ALDH1A2 expression in T-ALL. Interestingly, a high correlation coefficient of 0·60 was observed betweenALDH1A3 and TAL2 gene expression. T-ALL tumours uniformly appeared to be competent for RA signalling, with all specimens expressing all retinoid receptor (RAR/RXR) genes, with the exception of RXRG (Table 1) . RARA expression was particularly significant (Fig 1A) , as it exhibited strong overexpression in the tumours as compared to the normal thymus samples with a mean fold-change of 6·1 (P = 0·004).
T-all cell line proliferation is sensitive to inhibition of ALDH1A enzymes and RARA
The microarray results suggested that the RA pathway may be specifically relevant to T-ALL cell growth and/or survival. Consistent with this, RA has been documented to enhance normal human T cell proliferation (Dillehay et al, 1989; Ertesvag et al, 2002; Engedal et al, 2006) . To extend these findings to the tumour setting, we assessed the functional importance of RA synthesizing ALDH1A enzymes, together with RA signalling via RARA, to the proliferation of T-ALL cell lines (PER-117, PER-255, PER-604, CEM), which were compared with those of B lineage . All six cell lines tested were negative by microarray for ALDH1A1 and ALDH1A3 mRNA expression, but expressed varying levels of ALDH1A2 transcripts, with the two TAL1-positive T-ALL lines (PER-604 and CEM) very strongly expressing ALDH1A2 (Fig 2A) . All of the cell lines expressed the retinoid receptor (RAR/RXR) genes, with the exception of RXRG. Thus, the cell lines closely mirrored the primary T-ALL tumours in terms of the frequency of ALDH1A and RAR/RXR gene expression. To test whether the expression of the ALDH1A transcripts was reflected at the protein level, we used the Aldefluor assay to detect intracellular ALDH1A enzymatic activity in each of the cell lines. As shown in Fig 2B, enzyme activity correlated well with ALDH1A2 mRNA expression levels, and was notably higher in the T-ALL cell lines overall, as compared to those of B lineage.
ALL cell line growth was determined by MTT assay after exposure to the ALDH1A inhibitor citral (Kikonyogo et al, 1999) for 48 h. All four T-ALL cell lines tested showed sensitivity to citral with IC25 (concentration causing 25% inhibition of cell number) values varying from 55 to 130 μmol/l (Fig 3A) . Use of citral on the pre-B ALL cell lines, which had much lower ALDH1A activity, was significantly less effectual, with IC25 values of 160 and 250 μmol/l. Individually, the T-ALL line CEM was the most sensitive to ALDH1A inhibition, while the pre-B ALL PER-377 was the least sensitive. Of the T-ALL lines, PER-604 required the most citral to achieve 25% growth inhibition, which may reflect its very high level of ALDH1A activity. Reasoning that ALDH1A enzymes produce RA that signals via RA receptors, we next measured the effect of inhibiting both ALDH1A enzyme and RA receptor activity. Citral (at a constant concentration of 75 μmol/l) was therefore incubated with cells in combination with the RARA-selective antagonist Ro 41-5253. Similar to the results using citral alone, the T-ALL cell lines were found to be more sensitive than the pre-B ALL cell lines to inhibition of RA signalling via the RARA, with IC25 values for Ro 41-5253 being 8 to 48 μmol/l (T-lineage) compared with 60 and 85 μmol/l (B-lineage) (Fig 3B) . Conversely, in the presence of 75 μmol/l citral (to inhibit endogenous RA production), the T-ALL cell lines all responded positively to the addition of the pan-RAR agonist TTNPB, with SC25 (concentration causing 25% increase in cell number) values varying from 2·5 to 14 μmol/l (Fig 3C) . In sharp contrast, the B lineage cell lines did not benefit from pan-RAR stimulation by TTNPB, at least over the concentration range used, and thus SC25 values could not be derived. Together, these data indicate that T-ALL cells positively respond to signalling via retinoid receptors and that RAsynthesizing ALDH1A enzyme activity specifically contributes to cell growth in T-ALL.
Genes associated with cell proliferation, survival and differentiation correlate with ALDH1A expression in T-ALL tumours
We next sought to provide insight into the molecular basis by which aberrant expression of ALDH1A genes affect the proliferation and/or survival of T-ALL cells. One obvious mechanism by which ALDH1A enzyme activity could alter the cell phenotype is by activating nuclear RARs via production of RA to induce or repress the expression of downstream target genes. We therefore examined the transcriptional profile associated with ALDH1A2 among the 100 primary human T-ALL specimens. Functional evaluation of the top 200-correlated probe sets from this analysis revealed a significant association between ALDH1A2 expression and genes involved in cell proliferation, apoptosis and differentiation (Fig 4) . We focused on the most highly correlated 27 genes, 10 of which showed a positive and 17 an inverse correlation with ALDH1A2 ( Table 2) . As a proof of principle test to examine whether modulation of ALDH1A activity could affect the transcriptional level of correlated genes as putative downstream targets, we measured the mRNA levels of TNFRSF10B encoding TNFRSF10B (TRAIL-R2), which is associated with apoptosis and was strongly negatively correlated with ALDH1A2. This was achieved by real-time RT-PCR using RNA isolated from the four T-ALL cell lines (PER-117, PER-255, PER-604 and CEM) with and without treatment with 100 μmol/l citral.
RT-PCR was also performed using primers and probes specific for ALDH1A1 and ALDH1A2, as the promoters of these genes are reportedly subject to feedback regulation by the RA signalling pathway (Niederreither et al, 1997; Elizondo et al, 2000) . ALDH1A1 and ALDH1A2mRNA levels in the T-ALL cell lines approximately halved after ALDH1A inhibition whereas increases in TNFRSF10B mRNA levels of approximately two-fold were observed in three of the four T-ALL cell lines (Fig 5) . These results indicate that ALDH1A activity in the T lineage leads to repression of the apoptotic death receptor gene TNFRSF10B as well as activation of ALDH1A1 and ALDH1A2, possibly via a positive feedback loop.
Discussion
Understanding the molecular mechanisms by which T-ALL arises is essential in order to improve outcomes for patients. In this study, we have demonstrated that genes belonging to the aldehyde dehydrogenase 1A (ALDH1A) subfamily are aberrantly expressed in a large majority (close to three quarters) of childhood T-ALL tumours, but not in B-lineage ALL. ALDH1A2 expression was by far the most commonly observed (in 63% of T-ALL tumours) and showed a good correlation with TAL1 expression, consistent with previous studies indicating that TAL1/LMO transcriptional complexes are capable of regulating this gene (Ono et al, 1998) . In an additional finding, ALDH1A3 mRNA expression in a small number of tumours (3%) was highly correlated with that of the TAL2 oncogene, which warrants further investigation. Complete correlations were not observed between TLX1 and ALDH1A1, between TAL1 and ALDH1A2 nor between TAL2 and ALDH1A3, indicating that distinct mechanisms underlie the dysregulation of the various ALDH1A genes in T-ALL.
The main biological role of the enzymes encoded by ALDH1A genes is to convert the aldehyde form of vitamin A (retinal) to its biologically active form, RA (Molotkov & Duester, 2003) . Hence, ALDH1A enzymes are also known as retinal dehydrogenases (RALDHs). The tissue distribution and levels of RA are controlled by the activities of these enzymes, which have distinct roles in development and exhibit patterns of expression that are spatially and temporally regulated (Sládek, 2003) . This study therefore implicates ectopic synthesis of RA in thymocytes as a common event in the pathogenesis of T-ALL. RA mediates its crucial effects on cellular growth and development by acting as a ligand for nuclear RA receptors (RARs) and retinoid X receptors (RXRs).
Importantly, in all 100 T-ALL tumour specimens examined, all three RAR genes (RARA, RARB and RARG) and two of three RXR genes (RXRA, RXRB) were expressed. Moreover, the RARA gene was strongly upregulated in T-ALL (about 6-fold) as compared to normal thymus.
Thus, T-ALLs appeared uniformly competent to respond to cellular production of RA and seemingly with heightened sensitivity via RA receptor alpha (RARA).
A functional role for RA synthesis by ALDH1A enzymes and signalling via RARA in T-ALL growth was confirmed by blocking ALDH1A and RARA activity using specific inhibitors. We demonstrated that the proliferation of T-ALL cell lines had a higher sensitivity than B-lineage cell lines to ALDH1A and RARA inhibition. Conversely, treatment with a pan-RAR agonist specifically stimulated proliferation of the T-ALL cell lines while no such stimulation occurred in the B-lineage lines within the concentration range used. These data are consistent with previous studies in humans and mice which have shown that RA is stimulatory to T lymphocyte growth (Dillehay et al, 1989; Jiang et al,1993; Ertesvag et al, 2002; Seguin-Devaux et al, 2005; Engedal et al, 2006 ) but inhibitory to the growth of B lymphocytes (Bosma & Sidell,1988; Fahlman et al, 1995; Naderi & Blomhoff, 1999) , while promoting B cell differentiation (Chen et al, 2008) . This provides a plausible explanation for why aberrant ALDH1A expression is almost completely restricted to ALL tumours of T cell phenotype. One mechanism proposed to explain the T cell growth-promoting effect of RA involved stimulation of interleukin 2 signalling (Jiang et al, 1993; Ertesvaget al, 2002; Engedal et al, 2006) .
Consistent with this study, RA is also known to inhibit T cell apoptosis and block the negative selection of thymocytes. This has been demonstrated in vitro in thymocytes, T cell hybridomas, peripheral human T cells, as well as mouse thymocytes in vivo (Iwata et al, 1992; Bissonnette et al, 1995; Yang et al, 1995; Yagi et al, 1997; Szondy et al, 1998; Szegezdi et al, 2003; Engedal et al, 2004; Rasooly et al,2005) . Interference by retinoids in thymocyte negative selection is reportedly due to activation of RARA leading to inhibition of both DNA binding by nur77 and synthesis of the pro-apoptotic protein BCL2L11 (BIM) (Szegezdi et al, 2003) . Besides its roles in modulating T cell growth and survival, RA has been implicated as a negative regulator of thymocyte maturation (Meco et al, 1994; Napolitano et al, 1997; Zhou et al, 2008) . In either mouse fetal thymic organ cultures or thymuses obtained from young children, administration of RA halted thymocyte differentiation at the CD4+CD8+ double-positive stage of development (Yagi et al, 1997; Zhou et al, 2008) , the same stage at which TLX1 and TAL1 halt maturation in T-ALL (Ferrando et al, 2002) .
Taken together, previous work implicates RA as a critical signal for regulating normal thymocyte growth and development in vivo. That ALDH1A enzymes functionally underlie this RA synthesis in the thymus has been demonstrated using mutant mice carrying a hypomorphic allele of the Aldh1a2 gene. A major feature of these mice is thymic aplasia/hypoplasia resembling DiGeorge syndrome (Vermot et al, 2003) . Given that normal T cells do not express ALDH1A enzymes, and thus are unlikely to synthesize appreciable amounts of RA endogenously, a key question is where RA is produced in the thymus. Evidence to date points to the thymic microenvironment, which supports thymocyte survival and proliferation, specifically thymic stromal cells, which reportedly express ALDH1A enzymes and synthesize retinoids (Kiss et al, 2008) . Such a scenario, where functional cells require exogenous RA produced by accessory cells for their survival and development appears to be a common theme among a variety of physiological systems. For example, gonadal germ cell fate is dictated by RA produced by mesonephroi (Bowles et al, 2006) whereas astrocytes provide a regulated source of RA for the brain (Sheareret al, 2012) . RA is also provided to peripheral T lymphocytes by dendritic cells and this has been shown to imprint gut-homing specificity by enhancing the expression of integrin alpha4beta7 and chemokine receptor CCR9, an effect suppressed by the ALDH1A inhibitor citral (Iwata et al, 2004) . The regulation of haemopoietic stem cell (HSC) differentiation represents an interesting variation on this theme. In an inverse situation, HSCs are ALDH1A positive and produce their own RA, which primes their ability to undergo differentiation. However, the microenvironment, specifically bone marrow stromal cells, inactivate RA via CYP26B1 enzyme activity to control HSC fate and allow for HSC self-renewal (Ghiaur et al, 2013) .
Our microarray analysis additionally provided an insight into the gene expression signature associated with aberrant ALDH1A expression in T-ALL. In accord with our experimental data, genes correlated with ALDH1A2 (the most commonly and robustly expressed ALDH1Agene) were involved in cell proliferation, apoptosis and differentiation. This also fits with ALDH1A2 being listed as one of the genomic classifiers that distinguish induction failure patients with T-ALL (Winter et al, 2007) . Genes highly concordant with ALDH1A2 includedNUDT11 (nudix [nucleoside diphosphate linked moiety X]-type motif 11), which is involved in a variety of cellular functions and is implicated in cancer pathogenesis (Grisanzio et al, 2012) , BEX2 (brain expressed X-linked 2), which is linked to cell cycle regulation and apoptosis (Naderi et al, 2010) and whose product functionally interacts with LMO2 (Han et al, 2005) , and CDK5RAP3 (CDK5 kinase regulatory subunit-associated protein 3), which is associated with tumour metastasis (Mak et al, 2011) . Genes showing an inverse correlation withALDH1A2 included TNFSF10 (tumor necrosis factor [ligand] superfamily, member 10 encoding TNFSF10, also termed TRAIL), a TNF-related ligand that induces apoptosis especially in transformed cells (Wang & El-Deiry, 2003) , TNFRSF10B, (encoding TNFRSF10B, also termed TRAIL-R2/death receptor 5), a receptor for TNFSF10 whose low expression in T-ALL has been previously noted (Akahane et al, 2010) , and SOCS2 (suppressor of cytokine signalling 2), a key regulator of cytokine and various hormone signalling pathways that has been implicated in carcinogenesis (RicoBautista et al, 2006) . At least some of these genes may lie downstream of ALDH1A enzyme activity via RA activation of nuclear RARs. In particular, both TNFSF10 and TNFRSF10A (TRAIL-R1) are known to be regulated by RA (Altucci et al, 2001; Dhandapani et al, 2011) . Focusing on TNFRSF10B, we confirmed a functional link between ALDH1A activity and the repression of this gene in T-ALL, with ALDH1A inhibition resulting in an increase in TNFRSF10B mRNA levels. In parallel, ALDH1A enzyme inhibition led to a decrease in both ALDH1A1 and ALDH1A2 mRNA levels. This indicates that a positive feedback loop may be operational in T-ALL in which RA produced by ALDH1A activity leads to a chronic enhancement and stabilization of ALDH1A gene expression, reinforcing its oncogenic program. Given that hundreds of genes are regulated by RA, this program is likely to be complex and involve crosstalk with other pathways. For example, upregulation of NOTCH1 and/or repression of CDKN2A gene expression by RA (Linet al, 2003; You et al, 2000) could potentially synergize with activating mutations to NOTCH1 and hemizygous loss of CDKN2A,respectively, in T cell tumourigenesis.
In conclusion, our data suggest a model of leukaemogenesis in which the ability of thymocytes to endogenously synthesize RA independent of thymic stromal cells (following acquisition of ALDH1A
enzymatic activity e.g. downstream of TLX1 or TAL1) would lead to an unregulated expansion and arrested development of such cells within the thymus and promote malignancy. If substantiated, this may lead to more specific therapies for T-ALL, on the basis that it should be possible to target susceptible retinoid signalling pathway components with small-molecule inhibitors. Attempts at treating T-ALL with RA itself have, not surprisingly, been unsuccessful. On the contrary, our data indicate that treatment with RA might actually promote the development of T cell malignancy, based on its thymocyte pro-growth and anti-differentiation properties. Indeed, multiple cases of secondary T-ALL following differentiation therapy using RA for acute promyelocytic leukaemia have been reported (Bee et al, 2004; Szotkowski et al, 2009; Maschan et al, 2011) . Further studies are required to determine the extent to which aberrant retinoid signalling contributes to the T-ALL phenotype and whether deregulated ALDH1A gene expression is sufficient to initiate T cell leukaemogenesis. 
